What can you say
How do you advertise ketamine therapy without crossing the line?
Only one ketamine drug is approved for the mind, and it is not the one most clinics infuse.
Carefully, because most ketamine-for-depression marketing is off-label. Only esketamine, sold as Spravato, carries an FDA psychiatric indication; racemic ketamine does not. That turns efficacy claims into a substantiation problem under state medical-board advertising rules and lands the ad in a restricted or prohibited bucket on Google and Meta. Market the service, not the cure.
Ketamine hydrochloride is FDA-approved as an anesthetic, not a psychiatric medicine. The one ketamine-family drug with an approved psychiatric use is esketamine, sold as Spravato, cleared January 2025 as a monotherapy for treatment-resistant depression, plus earlier approvals with an oral antidepressant and for major depressive disorder with acute suicidal ideation. Racemic ketamine for depression is off-label. Off-label prescribing is legal; off-label promotion is the trap: presenting ketamine as approved or proven for depression describes a use the FDA has not evaluated.
Spravato (esketamine) is indicated for treatment-resistant depression in adults and for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior.
Every state board can discipline a licensee for false, deceptive, or misleading advertising. Texas's physician advertising chapter names two ketamine hazards: offering a permanent cure for an incurable condition, and claiming a unique or exclusive skill you cannot substantiate. Florida's Board of Medicine rule adds a ban on ads creating false or unjustified expectations of beneficial assistance. The test is substantiation: a measured service description is fine, but a cure rate or treating an off-label use as settled science gets a complaint referred.
No physician shall disseminate any advertisement that is in any way false, deceptive, or misleading, including offering a permanent cure for an incurable disease, sickness, and/or illness.
| State | How it differs | Citation |
|---|---|---|
| Texas | Board advertising rule bars false, deceptive, or misleading ads and, by name, offering a permanent cure for an incurable condition or claiming an unsubstantiated unique skill. | 22 TAC 164.3(b)(2), (b)(6) |
| Florida | Board of Medicine advertising rule bars the same and adds ads that create false or unjustified expectations of beneficial assistance. | Rule 64B8-11.001(2)(c), F.A.C. |
| Most states | A parallel board advertising rule plus the state deceptive-trade-practices act; the cure or proven-efficacy framing is the shared trigger. | State medical practice acts; UDAP statutes |
Even a clean, well-substantiated ad still has to clear the ad networks, and this is where ketamine marketing gets narrow. The platforms treat prescription-only and off-label mental-health promotion as a restricted or prohibited category, gate some drug terms behind certification, and revise the line often. Build the campaign to survive a policy that tightens, not one frozen at today's reading. The posture below is current and should be re-checked before each flight.
- GoogleThe healthcare and medicines policy, plus the unapproved-pharmaceuticals and restricted-drug-term rules, can suspend an account that promotes a drug as safe or effective for an unapproved use, and some drug terms now require certification to run at all.
- MetaPrescription-drug and health claims are restricted, and its Oversight Board has already ruled on ketamine promoted for non-FDA-approved uses, a clear signal that off-label efficacy claims are an enforcement target.
- Both networksThese rules move on the platforms' own schedule, not the law's. Treat any current approval as provisional and confirm the policy again before you relaunch.
The scanner reads the claim, not your chart. Here is the line that flags and the line that clears on the very same ketamine service.
FDA-approved ketamine: a proven cure for depression, results guaranteed.
Ketamine itself has no FDA-approved psychiatric indication, so calling it FDA-approved for depression is false, and 'proven cure' plus a guarantee is an unsubstantiated outcome claim a medical board treats as deceptive advertising.
Off-label efficacy and cure claims · 22 TAC 164.3; Rule 64B8-11.001, F.A.C.
We provide clinician-supervised ketamine infusions, used off-label for depression, and we will walk you through the evidence and the risks before you decide.
States the off-label status plainly, describes the actual service, and points to a real evidence conversation instead of promising a cure.
What are the rules for advertising a ketamine clinic?
Every state medical board can discipline a licensee for false, deceptive, or misleading advertising, and the specific triggers named on this page are cure claims and unsubstantiated efficacy claims. Texas's rule, 22 TAC 164.3, bars offering a permanent cure for an incurable condition and claiming an unsubstantiated unique skill. Florida's Rule 64B8-11.001(2)(c) F.A.C. adds a ban on creating false or unjustified expectations of beneficial assistance.
Do ketamine clinics need LegitScript certification to advertise?
This page does not name LegitScript specifically. What is certain from the sources cited above is that the Google healthcare and medicines policy gates some drug terms behind certification, and that posture shifts on the platform's own schedule. The honest move is checking the current policy before each flight rather than asserting a blanket certification requirement.
Can clinics advertise esketamine treatment?
Esketamine, sold as Spravato, is the one ketamine-family drug with an approved psychiatric indication, cleared under NDA 211243 as a monotherapy for treatment-resistant depression effective January 21, 2025. Advertising it can describe that approved use accurately, but Texas's 22 TAC 164.3 and Florida's Rule 64B8-11.001(2)(c) F.A.C. still bar any framing that turns the approval into a cure claim or a guaranteed result.
Can you say ketamine is FDA approved for depression?
No. Ketamine hydrochloride is FDA-approved as an anesthetic, not a psychiatric medicine; only esketamine, approved under NDA 211243, carries a psychiatric indication. Calling racemic ketamine FDA-approved for depression is a false claim under both 22 TAC 164.3 and Rule 64B8-11.001(2)(c) F.A.C.
Can you run ketamine ads on Google?
Sometimes, inside a restricted category. The Google healthcare and medicines policy can suspend an account that promotes a drug as safe or effective for an unapproved use, and some drug terms require certification to run at all. Because that policy moves on Google's own schedule, re-check it before each flight rather than relying on a prior approval.
What can a ketamine clinic say about results?
A measured description of the service holds up; a cure rate or a guaranteed outcome does not. Both 22 TAC 164.3 and Rule 64B8-11.001(2)(c) F.A.C. name the same trigger, offering a permanent cure or creating false or unjustified expectations of beneficial assistance. The pass example above on this page shows the fix: state the off-label status plainly and point to an evidence conversation instead of promising a cure.
Sources
Pre-Trip is a rigorous screen, not legal advice. Counsel decides; we help you arrive prepared.